Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial

免疫原性 肺炎球菌结合疫苗 医学 耐受性 肺炎球菌疫苗 人口 不利影响 结合疫苗 血清型 免疫学 抗原 内科学 儿科 肺炎链球菌 生物 微生物学 抗生素 环境卫生
作者
James Wassil,Maggie Sisti,Jeff Fairman,Matthew Davis,Carlos Fierro,Sean Bennett,Derek R. Johnson,Thi‐Sau Migone,Kien T. Nguyen,Paul Sauer,Michelle Currie,Sam Iki,Jakub K. Simon
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:24 (3): 308-318 被引量:10
标识
DOI:10.1016/s1473-3099(23)00572-8
摘要

Summary

Background

Despite substantial reductions in pneumococcal disease with the availability of pneumococcal conjugate vaccines, a significant burden of pneumococcal disease remains due to the diversity of serotypes combined with serotype replacement. We developed a new vaccine candidate, VAX-24 (24-valent pneumococcal conjugate vaccine), using cell-free protein synthesis to produce a variant of cross-reactive material 197 (eCRM) as the carrier protein, increasing serotype coverage while minimising carrier suppression. The aim of this clinical trial was to assess the safety, tolerability, and immunogenicity of three different doses of VAX-24 compared to pneumococcal 20-valent conjugate vaccine (PCV20).

Methods

This was a phase 1/2, randomised, double-masked study of VAX-24 versus PCV20 conducted in the USA. Key inclusion criteria included being a male or female aged 18 to 64 years in good health; key exclusion criteria included previous history of pneumococcal disease, receipt of a licensed or investigational pneumococcal vaccine, or immunosuppressive therapy. Participants were randomly allocated in a 1:1:1:1 ratio by permuted block to receive one dose of VAX-24 (1·1 μg of each antigen, 2·2 μg of each antigen, or 2·2 μg of 17 antigens mixed with 4·4 μg of seven antigens), or PCV20. The safety population included all participants with safety data. The immunogenicity population was as per-treatment in phase 2. Primary outcome measures included solicited and unsolicited adverse events. Secondary outcomes included serotype-specific opsonophagocytic activity (OPA) geometric mean titres (GMT), and IgG geometric mean concentrations (GMC) were measured 1 month postvaccination. Traditional non-inferiority criteria included OPA geometric mean ratio (GMR), with a lower bound of the two sided 95% CI of greater than 0·5 for shared serotypes. This completed trial is registered at ClinicalTrials.gov, NCT05266456.

Findings

Safety profiles were comparable among the treatment groups, with 170 of 209 participants (81%, 95% CI 75·2–86·2) to 178 of 207 participants (86%, 80·5–90·4) reporting at least one solicited adverse event among the three VAX-24 groups. 24 of 207 participants (12%, 7·6–16·8) to 32 of 209 of participants (15%, 10·7–20·9) experiened an unsolicited treatment emergent adverse event within 1 month postvaccination. VAX-24 2·2 μg met traditional OPA GMR non-inferiority criteria for all 20 shared serotypes; 16 serotypes elicited GMR point estimates greater than 1·0, and four reached the lower bound of the two-sided 95% CI greater than 1·0.

Interpretation

VAX-24 had a safety profile similar to PCV20 at all doses, with the 2·2 μg dose showing increased serotype coverage with decreased carrier suppression.

Funding

Vaxcyte.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Sea_U发布了新的文献求助10
1秒前
执着又蓝完成签到,获得积分20
2秒前
2秒前
量子星尘发布了新的文献求助10
3秒前
6秒前
9秒前
Sea_U完成签到,获得积分0
9秒前
坤坤完成签到,获得积分10
10秒前
彭于晏应助zwy109采纳,获得10
10秒前
小星星完成签到,获得积分20
10秒前
钱罐罐发布了新的文献求助10
11秒前
科研通AI5应助整齐百褶裙采纳,获得10
12秒前
13秒前
15秒前
16秒前
17秒前
有魅力乌发布了新的文献求助10
18秒前
adamchris应助不会做科研采纳,获得100
18秒前
晨曦发布了新的文献求助10
19秒前
Kris发布了新的文献求助10
20秒前
zwy109发布了新的文献求助10
22秒前
英姑应助钱罐罐采纳,获得10
22秒前
东耦完成签到,获得积分10
30秒前
打打应助Kris采纳,获得10
32秒前
32秒前
33秒前
情怀应助超级的鹅采纳,获得10
33秒前
33秒前
战斗暴龙兽完成签到,获得积分10
34秒前
34秒前
isojso完成签到,获得积分10
34秒前
34秒前
有魅力乌完成签到,获得积分10
34秒前
36秒前
37秒前
Lily发布了新的文献求助10
39秒前
40秒前
40秒前
41秒前
41秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988997
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253520
捐赠科研通 3269928
什么是DOI,文献DOI怎么找? 1804830
邀请新用户注册赠送积分活动 882063
科研通“疑难数据库(出版商)”最低求助积分说明 809068